AB-002 is under clinical development by Aronora and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AB-002’s likelihood of approval (LoA) and phase transition for Thrombosis took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AB-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AB002 (E-WE Thrombin) is under development for the treatment of thrombosis in end stage renal disease patients on chronic hemodialysis. It is administered through intravenous bolus. The bioengineered drug candidate targets protein C. The drug candidate is a recombinant antithrombotic and cytoprotective enzyme that acts without increasing the risk of bleeding. It was also under development for the treatment of high bleeding risk indications, such as acute stroke and heart attack, arterial thrombosis, multiple sclerosis, acute cardiovascular ischemia, cerebral ischemia.
Aronora operates in pharmaceutical and healthcare industry. It is headquartered in United States.
Quick View AB-002 LOA Data
|Highest Development Stage|